AC
CORT icon

Athanor Capital’s Corcept Therapeutics CORT Stock Holding History

Athanor Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-55,920
Closed -$1.33M – 505
2021
Q1 		$1.33M Buy
55,920
+38,548
+222% +$1.03M 0.03% 284
2020
Q4 		$454K Sell
17,372
-22,764
-57% -$480K 0.01% 491
2020
Q3 		$699K Buy
40,136
+12,241
+44% +$195K 0.03% 284
2020
Q2 		$469K Buy
+27,895
New +$392K 0.02% 315

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Athanor Capital's CORT Position: Q2 2021 in Review

Athanor Capital sold out of Corcept Therapeutics (CORT) in Q2 2021, closing a stake of 55,920 shares — an estimated $1.33M sold.

Athanor Capital first reported a position in CORT in Q2 2020 and held it in 4 quarters. The position peaked at $1.33M in Q1 2021. 199 funds tracked by Wall St. Rank hold CORT as of Q2 2021.

  • Athanor Capital reported no remaining Corcept Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 55,920 Corcept Therapeutics shares in Q2 2021, an estimated $1.33M.
  • Athanor Capital first reported a position in Corcept Therapeutics in Q2 2020 and held it in 4 quarters.
  • Athanor Capital's Corcept Therapeutics position peaked at $1.33M in Q1 2021.
  • 199 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.